中国现代医生2018，Vol.56Issue(13)：14-17,4.
乳腺癌原发灶和复发及转移灶中ER、PR、HER-2、Ki67的变化及其临床意义
The change and clinical significance of ER, PR, HER-2 and Ki67 in primary tumor, recurrence and metastasis of breast cancer
摘要
Abstract
Objective To investigate the difference of expression and its clinical significance of ER, PR, HER-2 and Ki67 in the primary tumor, recurrence and metastasis of breast cancer. Methods 70 patients with recurrence of breast cancer in our hospital were selected. The immunohistochemical expression of ER, PR, HER-2 and Ki67 in the primary tumor and corresponding recurrence and metastasis were analyzed respectively. Results The incidence of local recurrence and distant metastasis of breast cancer was significantly associated with tumor grade(P=0. 000) and tumor TNM stage(P=0. 002)(P＜0. 05). The incidence of them was not significantly associated with age of patient(P=0. 873), menopause (P=0. 540) and axillary lymph node metastasis(P=0. 556). The χ2 test was used to examine the difference of expression before and after the primary tumor, recurrence and metastasis (ER: χ2=0. 507,P=0. 476; PR: χ2=0. 714, P=0. 398; HER-2: χ2=2. 287, P=0. 130; Ki67:χ2=10. 683, P=0. 001), suggesting the overall distribution of the expression of ER, PR and HER-2 was not statistically different(P＞0. 05) and the overall distribution of Ki67 expression was statistically different (P＜0. 05). The expression of ER, PR and Ki67 in recurrence and metastasis was significantly consistent(P＜0. 05). Conclusion The expression of ER, PR and Ki67 in primary tumor, recurrence and metastasis was inconsistent while the expression of HER-2 was highly consistent. Assessment of the expression of these biomarkers in recurrence and metastasis of breast cancer was important for individualized treatment regimen selection and the evaluation of prognosis.关键词
乳腺癌/原发灶/复发/转移/ER/PR/HER-2/Ki67Key words
Breast cancer/Primarytumor/Recurrence/Metastasis/ER/PR/HER-2/Ki67分类
医药卫生引用本文复制引用
朱磊,潘颖,周毅,程枫,程雪..乳腺癌原发灶和复发及转移灶中ER、PR、HER-2、Ki67的变化及其临床意义[J].中国现代医生,2018,56(13):14-17,4.基金项目
浙江省医药卫生一般研究计划项目(2016KYA201) （2016KYA201）
